

UC Davis

UC Davis Previously Published Works

Title

White Matter Lesion Progression

Permalink

<https://escholarship.org/uc/item/2ns4g2jw>

Journal

Stroke, 46(11)

ISSN

0039-2499

Authors

Hofer, Edith
Cavalieri, Margherita
Bis, Joshua C
[et al.](#)

Publication Date

2015-11-01

DOI

10.1161/strokeaha.115.009252

Peer reviewed



Published in final edited form as:

Stroke. 2015 November ; 46(11): 3048–3057. doi:10.1161/STROKEAHA.115.009252.

White matter lesion progression: A genome-wide search for genetic influences

A full list of authors and affiliations appears at the end of the article.

Abstract

Background and Purpose—White matter lesion (WML) progression on magnetic resonance imaging (MRI) is related to cognitive decline and stroke, but its determinants besides baseline WML burden are largely unknown. Here, we estimated heritability of WML progression, and sought common genetic variants associated with WML progression in elderly participants from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium.

Methods—Heritability of WML progression was calculated in the Framingham Heart Study. The genome-wide association study included 7773 elderly participants from 10 cohorts. To assess the relative contribution of genetic factors to progression of WML, we compared in seven cohorts risk models including demographics, vascular risk factors plus single nucleotide polymorphisms (SNPs) that have been shown to be associated cross-sectionally with WML in the current and previous association studies.

Results—A total of 1085 subjects showed WML progression. The heritability estimate for WML progression was low at 6.5%, and no SNPs achieved genome-wide significance (p -value $< 5 \times 10^{-8}$). Four loci were suggestive (p -value $< 1 \times 10^{-5}$) of an association with WML progression: 10q24.32 (rs10883817, $p=1.46 \times 10^{-6}$); 12q13.13 (rs4761974, $p=8.71 \times 10^{-7}$); 20p12.1 (rs6135309, $p=3.69 \times 10^{-6}$); and 4p15.31 (rs7664442, $p=2.26 \times 10^{-6}$). Variants that have been previously related to WML explained only 0.8% to 11.7% more of the variance in WML progression than age, vascular risk factors and baseline WML burden.

Conclusions—Common genetic factors contribute little to the progression of age-related WML in middle-aged and older adults. Future research on determinants of WML progression should focus more on environmental, life-style or host-related biological factors.

Corresponding author: Reinhold Schmidt, Medical University of Graz, Department of Neurology, Division of Neurogeriatrics, Auenbruggerplatz 22, 8036 Graz, Austria, Fax: +43 316 385 14178, Phone: +43 316 385 13136, reinhold.schmidt@medunigraz.at.

Disclosures

Dr Amouyel has received personal fees from Servier, Hoffman Laroche, Total, Genoscreen, Alzprotect and Fondation Plan Alzheimer. Dr Dufouil has received payment for lectures from the American Academy of Neurology. Dr Lumley has received support for travel from the National Heart, Lung, and Blood Institute. Dr Niessen is co-founder and scientific director of Quantib BV and owns stock/stock options from Quantib BV. Dr Phan is member of the Advisory Board for Genzyme on Fabry Disease and has received payment for lectures from Bayer, Pfizer, Genzyme and Boehringer Ingelheim. Dr Psaty has provided service on DSMB for a clinical trial of a device by the manufacturer (Zoll LifeCor) and service on a Steering Committee for the Yale Open Data Access Project funded by Johnson & Johnson. Dr R Schmidt has received consulting fees from Axon Neurosciences, Avraham Pharmaceuticals and Pfizer. Dr Verhaaren has received support for travel from Nederlandse Hartstichting, 2009B102. Dr Zijdenbos has received consulting fees and support for travel from the National Institute on Aging and has been employed or is currently employed at Prodeema Medical, Montreal Neurological Institute and Biospective Inc. The other authors report no conflicts.

Keywords

magnetic resonance imaging; aging; cerebral small vessel disease

Introduction

The etiology of white matter lesions (WML) on magnetic resonance imaging (MRI) is still incompletely understood. WML burden was shown to be highly heritable.¹⁻³ Age and hypertension are the main known risk factors for WML but explain only a small proportion of lesion presence and burden.⁴ Prior to the era of genome-wide association studies (GWAS) candidate gene studies investigated variants in 19 genes and found associations between WML extent and polymorphisms in the apolipoprotein E, the methyltetrahydrofolate reductase, the angiotensin-converting enzyme and the angiotensinogen genes.^{5, 6} Moreover, genetic variants in the NOTCH3 gene may not only play a role in CADASIL, a monogenic cerebral small vessel disease, but are also likely to be involved in the etiology of age-related WML burden.⁷ In 2011, the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium⁸ performed the first genome-wide association study on WML burden in the general population.⁹ The CHARGE investigators identified 6 SNPs mapping to a locus on chromosome 17q25 to be related to WML burden. The findings of the discovery meta-analyses had been confirmed in an independent sample of 1607 AGES-Reykjavik participants and in 1417 and 1677 elderly white participants from the Three-City-Dijon Study⁹ and the Rotterdam Study III¹⁰ as well as in a study of WML burden in persons with a clinical ischemic stroke.¹¹ The association was also confirmed in an Asian population including 1190 Japanese persons with a mean age of 66 years.¹² The region on chromosome 17 is approximately 100 kb long and harbors several genes with diverse functions such as the 2 tripartite motif-containing genes (*TRIM65* and *TRIM47*) the WW domain binding protein 2 gene (*WBP2*), the mitochondrial ribosomal protein L38 gene (*MRPL38*), the Fas-binding factor 1 gene (*FBF1*), the acyl-coenzyme A oxidase 1 gene (*ACOX1*) and the C-Elegans homolog (*UNC13D*) gene. Although genetic factors may play an important role in the occurrence of WML in middle-aged to older adults, whether these genes or others influence the further progression of WML is unknown. Using data on WML progression from all the cohorts currently available within the CHARGE consortium, we examined the heritability of WML progression and performed a meta-analysis of GWAS data in 7773 individuals of European descent from 10 cohorts to identify common single nucleotide polymorphisms (SNPs) that influence the risk for WML progression. We also assessed the relative contribution of genetic factors in predicting WML progression beyond information that can be obtained from baseline clinical and MRI data alone.

Materials and Methods

Study Population

Study participants were from 10 prospective cohort studies collaborating in the CHARGE Consortium⁸: the Aging Gene-Environment Susceptibility Reykjavik Study (AGES-Reykjavik)¹³, the Atherosclerosis Risk in Communities (ARIC) study¹⁴, the Austrian Stroke Prevention Study (ASPS)^{15, 16}, the Cardiovascular Health Study (CHS)¹⁷, the Framingham

Heart Study (FHS)^{18, 19}, the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)^{20, 21}, the Rotterdam Study II (RS II) and the Rotterdam Study III (RS III)²², the Tasmanian Study of Cognition and Gait (TASCOG)²³ and the 3C-Dijon study.²⁴ All participating studies agreed on phenotype harmonization, covariate selection, pre-specified analytic plans for within-study analyses, and meta-analysis of results. Each study secured approval from Institutional Review Boards, and all participants provided written informed consent for study participation, MRI scanning, and use of DNA for genetic research.

Participants were eligible for the current study if they had genotyping, serial MRI, and lacked a history of transient ischemic attacks, strokes, dementia, or any combination of these conditions. All the individuals in the present analysis were whites of European descent. The number of participants and their characteristics in each cohort are shown in Supplemental Table I in the online-only Data Supplement.

WML Progression Assessment

In each study, eligible participants were invited to undergo serial MRI scans, which were performed and interpreted in a standardized fashion without knowledge of demographic, clinical or genetic information (Section II in the online-only Data Supplement). Except for ARIC and CHS whose readers used a 10-point scale, readers in the other cohorts measured the volume of WML on each MRI scan. WML progression was defined as absent or present (Section III in the online-only Data Supplement). In brief, WML progression was considered to be present if visual rating increased by at least 1 grade between baseline and follow-up in ARIC and CHS, or if WML volume increased by at least one standard deviation of the study-specific mean of volume change in AGES-Reykjavik, ASPS, FHS, PROSPER, RS II, RS III, TASCOG and 3C-Dijon. WML regression was rare in all studies and was not considered separately in these analyses.

Genotyping

The consortium was formed after individual studies had finalized their GWAS platforms, which differed across studies. All studies used their genotype data to impute to the 2.5 million non-monomorphic, autosomal, single nucleotide polymorphisms (SNPs) described in HapMap's European population panel. Extensive quality control analyses were performed in each cohort. Details on the genotyping, quality control and imputation efforts are described in Supplemental Tables II - IV in the online-only Data Supplement.

Heritability of WML Progression

Heritability of WML progression was calculated based on family structure in FHS, which is the only family study among the participating cohorts. Calculations were based on annual WML change and two models were assessed. The first model adjusted for age and sex, while the second model additionally adjusted for WML volume at baseline. The ratio of the genetic variance to the phenotypic variance in FHS was determined using variance component models in SOLAR.²⁵

Genome-wide association analyses (GWAS)

For the GWAS each study fitted an additive genetic model with a 1-degree-of-freedom trend test relating genotype dosage, 0 to 2 copies of the minor allele, to presence or absence of WML progression. We used logistic regression models to calculate regression estimates with corresponding standard errors. Initial analyses were adjusted for age, sex, interval between scans as well as principal components of population structure if appropriate. Subsequent analyses included additional adjustment for WML volume at baseline. In addition, ARIC and CHS also adjusted for study site, and FHS, for familial structure. We then conducted a meta-analysis of logistic regression estimates and standard errors using a fixed effects inverse-variance weighting approach with genomic control correction as implemented in METAL.²⁶

There was no evidence of inflated test statistics in the individual cohort analyses (Figures I and II in the online-only Data Supplement).

The genome-wide significance threshold was set a priori at 5×10^{-8} . Associations were considered highly suggestive for SNPs with $5 \times 10^{-8} < p < 1 \times 10^{-5}$.

To evaluate if the lengths of the observational period influenced the effect size of highly suggestive SNPs and WML progression we performed GWAS meta-analyses separately for cohorts with short mean follow-up and those with long mean follow-up time. Short-term studies were AGES-Reykjavik, PROSPER and TASCOC. Long-term cohorts were ARIC, ASPS, CHS and FHS (for follow-up intervals between scans see Supplemental Table I in the online-only Data Supplement). Identical analyses were also done for younger (ARIC, ASPS, FHS, RSII and RSIII) and older (AGES-Reykjavik, CHS, PROSPER, TASCOC and 3C-Dijon) cohorts (for mean age of cohorts see Supplemental Table I in the online-only Data Supplement). The meta-analysis regression coefficients β of the SNPs were then compared between the investigational subsets using a z-test.

Annotation

Key SNPs were functionally annotated with SNPnexus²⁷ and ANNOVAR.²⁸ The SNAP²⁹ web application of the Broad Institute was used to determine linkage-disequilibrium (LD). Regional association plots were generated with LocusZoom.³⁰ Furthermore we used the NCBI Genotype-Tissue Expression eQTL Browser³¹ to check if a given SNP was associated with a quantitative gene expression trait.

Performance of WML progression risk models

To estimate the relative importance of genetic factors for progression of WML we compared the explained variance between three models in ASPS, CHS, FHS, PROSPER, RS II, RS III, and 3C-Dijon. Model 1 served as the reference and included age, sex, hypertension, diabetes, current smoking and the time interval between scans; model 2 included model 1 variables and those SNPs with the lowest p-value at each highly suggestive locus according to the present GWAS meta-analysis with adjustment for WML burden at baseline. We also included a missense SNP identified by annotation analyses. Model 3 included all model 2 variables plus genetic polymorphisms which were shown to be associated with WML in

previous publications.^{5, 7, 9, 32-43} We included only those SNPs for which an association with WML was reported by at least 2 studies. In case that any of these SNPs was not present in our database, a proxy SNP ($r^2 > 0.8$) was selected to be included.⁹ Based on this search strategy we selected ACE^{5, 32-34} (rs4343), MTHFR^{5, 35, 36} (rs1801133), AGT^{5, 37-39} (rs2478539), TRIM47⁹ (rs1055129), TRIM65⁹ (rs3744028), NOTCH3⁷ (rs10404382) and APOE4^{5, 40-43} genotypes to be included in model 3. APOE4 status was included as a binary variable (E4+ included the e3/e4 and e4/e4 genotypes; E4- included e2/e2, e2/e3 and e2/e4 genotypes). The three models were also calculated with additional adjustment for WML volume at baseline. Models 2 and 3 were adjusted for principal components of population structure if appropriate. The goodness of fit for each model was assessed by Nagelkerke's R^2 .^{44, 45}

Results

The analyses included 7773 participants from 10 cohort studies (Supplemental Table I in the online-only Data Supplement). A total of 4342 (56%) of study participants were women; 4030 (52%), hypertensive; and 690 (8.9%), diabetic. The mean systolic blood pressure ranged between 121.9mmHg and 157.8mmHg and the mean diastolic blood pressure between 69.6mmHg and 86.5mmHg. The mean time interval between the baseline and follow-up MRI was shortest in AGES-Reykjavik with 29.1 months and longest in ARIC with 123.6 months. Overall, WML progression was observed in 1085 (14.0%) study participants with the study-specific mean annual volume increase ranging between 0.2 cm³ and 1.4 cm³. The association between mean WML volume at baseline and mean annual volume increase in our cohorts was moderate (Pearson correlation coefficient $r=0.59$), but did not reach statistical significance (p -value=0.095). The relationship for each cohort is displayed in Supplemental Figure III in the online-only Data Supplement.

Heritability of WML progression

After adjustment for age and sex the heritability estimate for WML progression observed in 1368 FHS individuals was 6.5%. Additional adjustment for WML burden at baseline resulted in a heritability estimate of 4.7%.

Genome-wide associations of WML progression

Figure 1 illustrates the meta-analysis results of genome-wide association analyses on WML progression without and with adjustment for WML burden at baseline. In both meta-analyses no SNPs achieved genome wide significance (p -value $< 5 \times 10^{-8}$). Meta-analysis without adjustment for WML burden at baseline revealed 45 SNPs in 7 loci on 7 chromosomes with a highly suggestive association with WML progression at p -values $< 1 \times 10^{-5}$ (Supplemental Table V in the online-only Data Supplement). After additional adjustment for WML burden at baseline, 8 highly suggestive associations were identified (Supplemental Table VI in the online-only Data Supplement). These SNPs are located in 6 loci on 6 chromosomes. There is an overlap of four suggestive loci (1q41, 5q12.1, 12q13.13 and 13q34) between the two meta-analysis results. In the meta-analysis without adjustment for WML burden at baseline 35 of 45 suggestive SNPs in total were located at 10q24.32. The SNP rs10883817 had the lowest p -value (1.46×10^{-6}) at this locus, with an odds ratio

(OR) of 1.27, a mean minor allele frequency of 0.41, and a mean imputation quality score of 0.98. The suggestive variants at locus 10q24.32 were in LD (r^2 between 0.336 and 1) and reside either in introns of genes AS3MT, CNNM2, NT5C2, in the intergenic regions between these genes, or in exons of CNNM2 and NT5C2 (Figure 2 A).

At the second locus of interest, 12q13.13, we identified 3 highly suggestive variants in the analysis without adjustment for WML burden at baseline and only 1 with adjustment. In the meta-analysis without adjustment for baseline WML burden rs4761974 had the lowest p-value (8.71×10^{-7}), with an odds ratio of 0.5. After additional adjustment for baseline WML volume the p-value of the association changed to 2.94×10^{-6} (OR=0.5). The SNP had a mean minor allele frequency of 0.057 and a mean imputation quality score of 0.98. Suggestive SNPs at this locus were in high LD (r^2 between 0.786 and 1) and are located either in introns or in close proximity to the gene SLC4A8 (Figure 2 B).

At the third locus 20p12.1 in the analysis without adjustment for WML burden at baseline, the top SNP was rs6135309 with a p-value of 3.69×10^{-6} , an odds ratio of 0.78, a mean minor allele frequency of 0.29, and a mean imputation quality score of 0.97. Both suggestive variants at this locus were in LD ($r^2=0.642$) and reside in introns of MACROD2 (Figure 2 C). The fourth locus suggestive of an association with WML progression was located on chromosome 4p15.31 in the analysis with adjustment for WML burden at baseline. The top SNP at this locus was rs7664442 (p-value= 2.26×10^{-6} ; OR=0.65), which had a mean minor allele frequency of 0.079 and a mean imputation quality score of 0.96. These three SNPs at 4p15.31 were in perfect LD ($r^2=1$) and are located in the intergenic region near GBA3 (Figure 2 D).

Functional annotation of all highly suggestive SNPs and SNPs in linkage-disequilibrium with them was performed. The two suggestive exonic variants at locus 10q24.32, rs2275271 (p-value= 2.26×10^{-6} , OR=0.79) and rs3740387 (p-value= 5.10×10^{-6} , OR=1.25), were synonymous. Two other suggestive SNPs at this locus have been reported in previous genome-wide association studies investigating schizophrenia⁴⁶⁻⁴⁸ (rs7897654; p-value= 5.26×10^{-6} , OR=0.79 and rs7914558; p-value= 2.14×10^{-6} , OR=1.26). No association between suggestive SNPs and quantitative gene expression traits could be determined. A comparison of the effect size of suggestive SNPs on WML progression between studies with short versus long term follow-up failed to demonstrate significantly increased effect sizes in studies with long-term follow-up. There were also no significant differences in the effect sizes of suggestive SNPs on WML progression between younger and older cohorts (data not shown).

Performance of WML progression risk models

As can be seen from Table 1, model 1, which included demographics and risk factors, explained between 2.3% and 14.9% of the variance in WML progression in the various cohorts. Amongst studies that assessed WML progression by volume change, 17.2% to 43.3% of the WML progression variance was explained if baseline WML was included (model 1). In CHS, which used a visual rating scale for assessment of WML progression, only 4.5% of the variance could be explained. Highly suggestive SNPs from the current GWAS and all genetic variants previously described as being related to WML accounted for

additional 1.1% to 8.6% (model 2) and 0.8% to 11.7% (model 3) of the variance of WML progression beyond age, sex, vascular risk factors and baseline WML volume.

Discussion

In this first genome-wide association study on WML progression, our data indicate that genetic factors contribute only little to WML progression in the general elderly population. This conclusion relies on three major findings. First, the family-based heritability estimate for WML progression was only 6.5% versus a heritability of 55% for baseline WML burden in the same sample.² Second, our genome-wide analysis yielded no associations at a genome-wide significance level. Third, risk prediction models including highly suggestive SNPs according to the present GWAS meta-analysis plus all genetic polymorphisms that have been shown to be associated with WML burden in previous literature explained only between 0.8% and 11.7% more of the variance of WML progression than that explained by baseline clinical and MRI data. These results for WML progression oppose previous cross-sectional studies in which the contribution of genetic factors for WML burden was substantial.^{5, 7, 9, 32-43} This finding is puzzling because cross-sectionally assessed WML burden and WML progression are both quantitative measures with presumably the same biological basis. In this context it is of note, however that in our study initial burden of WML predicted annual WML volume increase moderately, but this relationship was not significant. Moreover, for both, brain volume and cognitive functions, similar results of limited genetic variance in longitudinal measures have been shown.⁴⁹⁻⁵¹ In line with our findings on white matter lesions these investigations also found that measures of brain atrophy and cognitive performance assessed cross-sectionally are highly heritably but predominantly environmental factors account for the rate of change of these cerebral phenotypes over time.

We identified four suggestive loci for WML progression on chromosomes 10q24.32, 12q13.13, 20p12.1 and 4p15.31. None of the SNPs in these loci reached genome-wide significance; however, some of the neighboring genes within these loci have been related to neuropsychiatric or vascular diseases.

Locus 10q24.32 includes AS3MT (arsenic (+3 oxidation state) methyltransferase), CNNM2 (Cyclin M2) and NT5C2 (5'-nucleotidase, cytosolic II). These genes have previously been identified to be associated with schizophrenia^{46-48, 52, 53} and blood pressure⁵⁴⁻⁵⁷ in GWAS and replication studies. CNNM2 and NT5C2 were associated with coronary artery disease,⁵⁸ and CNNM2 was additionally associated with intracranial aneurysm.⁵⁹ Moreover, a suggestive variant in an intron of AS3MT, rs10748835 (p-value=2.79×10⁻⁶, OR=1.25), is known to modify cognitive function in persons with low-level arsenic exposure.⁶⁰

The locus at 12q13.13 includes SLC4A8, a sodium bicarbonate co-transporter of the designated solute carrier family 4. It transports sodium and bicarbonate ions across the cell membrane.^{61, 62} The gene is highly expressed in all major regions of the brain and is involved in pH regulation in human neurons.⁶³

MACROD2 (MACRO domain containing 2) at locus 20p12.1 is a protein-coding gene that has been found to be associated with MRI-defined brain infarcts in a previous GWAS.⁶⁴ This is particularly intriguing as recent studies have suggested new lacunes are most likely to develop in areas of white matter progression.⁶⁵ MACROD2 has also been associated with autistic traits.⁶⁶

Although we included a large number of participants from ten cohort studies with longitudinal assessment of WML change, we cannot exclude the possibility that we missed significant associations of WML progression to SNPs with small effect sizes or low risk allele frequencies. Moreover, three other factors need to be considered when interpreting our results. First, we used a binary phenotype based on visual rating or cut-off values of volumetric change to define WML progression. This conservative definition decreased the likelihood of false positive ratings but, among those with WML at baseline, might have led to an underestimation of WML progression. Second, the average time period between scans among contributing cohorts was 54 months, and despite the fact that single studies had followed their participants for more than 10 years, it is conceivable that this period was too short to reveal the full impact of genetic factors on WML progression. Our findings that the effect sizes of suggestive GWAS SNPs on WML progression were not significantly larger in cohorts with long-term follow-up versus cohorts with short-term follow-up and in older versus younger cohorts do not support this assumption. Third, we by design concentrated on elderly people. Genetic factors may play a larger role for white matter progression in younger populations.

Our study findings have important implications for future research on age-related white matter changes. They suggest that, although the contribution of genetic factors seems to be large during the initiating phase of white matter damage, the propagating phase of WML appears to be mainly influenced by non-genetic determinants. With the exception of high blood pressure these non-genetic risk factors for WML progression remain largely unknown.^{67, 68} Based on current data, we need to intensify the search for potentially modifiable environmental and lifestyle factors that influence the progression of age-related white matter changes and the associated morbidity. Moreover, while this study focused on the influence of genetics on age-related WML progression, the effects of heritability on injury-induced WML progression are an interesting direction for future studies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Edith Hofer, PhD^{1,2}, Margherita Cavalieri, MD¹, Joshua C Bis, PhD³, Charles DeCarli, MD⁴, Myriam Fornage, PhD^{5,6}, Sigurdur Sigurdsson, MSc⁷, Velandai Srikanth, PhD⁸, Stella Trompet, PhD^{9,10}, Benjamin FJ Verhaaren, MD PhD^{11,12}, Christiane Wolf, PhD^{13,14}, Qiong Yang, PhD¹⁵, Hieab HH Adams, MSc^{11,12}, Philippe Amouyel, MD PhD¹⁶, Alexa Beiser, PhD¹⁵, Brendan M Buckley, MD PhD¹⁷, Michele Callisaya, PhD⁸, Ganesh Chauhan, PhD^{13,18}, Anton JM de Craen,

PhD¹⁰, Carole Dufouil, PhD¹³, Cornelia M van Duijn, PhD^{11,19}, Ian Ford, PhD²⁰, Paul Freudenberger, MSc²¹, Rebecca F Gottesman, MD PhD²², Vilmundur Gudnason, MD PhD^{7,23}, Gerardo Heiss, MD PhD²⁴, Albert Hofman, MD PhD¹¹, Thomas Lumley, PhD²⁵, Oliver Martinez, PhD⁴, Bernard Mazoyer, MD PhD²⁶, Chris Moran, MB BCH⁸, Wiro J. Niessen, PhD^{27,28}, Thanh Phan, PhD⁸, Bruce M Psaty, MD MPH PhD^{3,29}, Claudia L Satizabal, PhD³⁰, Naveed Sattar, MD PhD³¹, Sabrina Schilling, MSc^{13,18}, Dean K Shibata, MD³², P Eline Slagboom, PhD³³, Albert Smith, PhD^{7,23}, David J Stott, MD PhD³¹, Kent D Taylor, PhD^{34,35}, Russell Thomson, PhD³⁶, Anna M Töglhofer, MSc²¹, Christophe Tzourio, MD PhD³⁷, Mark van Buchem, MD PhD³⁸, Jing Wang, PhD¹⁵, Rudi GJ Westendorp, MD PhD^{10,39}, B Gwen Windham, MD⁴⁰, Meike W Vernooij, MD PhD^{11,12}, Alex Zijdenbos, PhD⁴¹, Richard Beare, PhD^{8,42}, Stéphanie Debette, MD PhD^{13,18,30}, M Arfan Ikram, MD PhD^{11,12}, J Wouter Jukema, MD PhD^{9,43,44}, Lenore J Launer, PhD⁴⁵, W T Longstreth Jr, MD⁴⁶, Thomas H Mosley, PhD⁴⁰, Sudha Seshadri, MD³⁰, Helena Schmidt, MD PhD^{1,21}, and Reinhold Schmidt, MD¹ **on behalf of the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium**

Affiliations

¹Department of Neurology, Medical University of Graz, Graz, Austria ²Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria ³Cardiovascular Health Research Unit, Departments of Medicine, University of Washington, Seattle, WA, USA ⁴Department of Neurology and Center for Neuroscience, University of California at Davis, Sacramento, CA, USA ⁵Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, USA ⁶Human Genetics Center, University of Texas Health Science Center, Houston, TX, USA ⁷Icelandic Heart Association, Kopavogur, Iceland ⁸Stroke and Ageing Research Group, Department of Medicine, Southern Clinical School, Monash University, Melbourne, Victoria, Australia ⁹Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands ¹⁰Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands ¹¹Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands ¹²Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands ¹³INSERM U897, Université Bordeaux Segalen, Bordeaux, France ¹⁴Department of Statistical Genetics, Max Planck Institute of Psychiatry, Munich, Germany ¹⁵Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA ¹⁶INSERM U744, Pasteur Institute, Lille, France ¹⁷Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland ¹⁸INSERM U1161 and Lariboisière Hospital, Paris 7 University, Paris, France ¹⁹Centre for Medical Systems Biology, Leiden, The Netherlands ²⁰Robertson Center for Biostatistics, University of Glasgow, Glasgow, United Kingdom ²¹Research Unit for Genetic Epidemiology, Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Graz, Austria ²²Department of Neurology, Johns Hopkins University, Baltimore, MD, USA ²³University of Iceland, Reykjavik, Iceland ²⁴Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA ²⁵Department of Statistics, University of

Auckland, Auckland, New Zealand ²⁶CNRS-CEA UMR5296, Université Bordeaux Segalen, Bordeaux, France ²⁷Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands ²⁸Faculty of Applied Sciences, Delft University, Delft, The Netherlands ²⁹Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA ³⁰Department of Neurology, Boston University School of Medicine, Boston, MA, USA ³¹Institute of Cardiovascular and Medical Sciences, Faculty of Medicine, Glasgow, United Kingdom ³²Department of Radiology, University of Washington, Seattle, WA, USA ³³Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands ³⁴Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute, Los Angeles, CA, USA ³⁵Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA ³⁶Menzies Research Institute, Hobart, Tasmania, Australia ³⁷INSERM U708, Université Bordeaux Segalen, Bordeaux, France ³⁸Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands ³⁹Department of Public Health, University of Copenhagen, Copenhagen, Denmark ⁴⁰Department of Medicine, University of Mississippi, Jackson, MS, USA ⁴¹Biospective Inc., Montréal, Quebec, Canada ⁴²Developmental Imaging, Murdoch Childrens Research Institute, Royal Childrens Hospital, Parkville, Victoria, Australia ⁴³Durrer Center for Cardiogenetic Research, Amsterdam, The Netherlands ⁴⁴Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands ⁴⁵National Institute on Aging, Bethesda, MD, USA ⁴⁶Departments of Neurology and Epidemiology, University of Washington, Seattle, WA, USA

Acknowledgements

ARIC thank the staff and participants of the ARIC study for their important contributions. ASPS thank the staff and the participants of the ASPS for their valuable contributions. 3C-Dijon thank the staff and the participants of the 3C Study for their important contributions. 3C-Dijon thank Anne Boland (Centre National de Génotypage, Institut de Génomique, CEA) for her technical help in preparing the DNA samples for analyses.

Study concept/design: R.S., H.S., S.S., C.D.; Data analysis: E.H., M.C.; Manuscript preparation: E.H., M.C., R.S., H.S.; Cohort contributions (alphabetical order): Study concept/design: AGES-Reykjavik: L.L., V.G.; ARIC: M.F., T.M.; ASPS: H.S., R.S.; CHS: B.P., W.L.; FHS: S.S.; PROSPER: B.B., I.F., D.S., N.S., R.W., J.W.; RS: M.I.; TASCOC: V.S.; 3C-Dijon: C.D., C.T.; Phenotype data acquisition/QC: AGES-Reykjavik: S.S., M.v.B., A.Z.; ARIC: D.S., G.W., R.G., G.H., T.M.; ASPS: H.S., R.S.; CHS: B.P., W.L.; FHS: A.B., C.D.; PROSPER: B.B., I.F., D.S., N.S., R.W., J.W.; RS: M.V., W.N., M.I.; TASCOC: V.S., T.P., M.C., C.M., R.B.; 3C-Dijon: C.D., B.M., C.T.; Genotype data acquisition/QC: AGES-Reykjavik: A.S.; ARIC: M.F.; ASPS: H.S., P.F.; CHS: J.B., T.L., K.T.; FHS: J.W., Q.Y.; PROSPER: S.T., J.W., E.S., A.C.; RS: A.H., C.v.D.; TASCOC: R.T.; 3C-Dijon: C.W., S.D., G.C., P.A.; Data analysis: AGES-Reykjavik: A.S.; ARIC: M.F.; ASPS: E.H., M.C., A.T.; CHS: J.B., T.L.; FHS: J.W., Q.Y.; PROSPER: S.T.; RS: B.V., H.A.; TASCOC: R.T.; 3C-Dijon: C.W., S.D., G.C., S.S.; Critical revision of manuscript for Important Intellectual content: E.H., M.C., J.B., C.D., M.F., S.S., V.S., S.T., B.V., C.W., Q.Y., H.A., P.A., A.B., B.B., M.C., G.C., A.d.C., C.D., C.v.D., I.F., P.F., R.G., V.G., G.H., A.H., T.L., O.M., B.M., C.M., W.N., T.P., B.P., C.S., N.S., S.S., D.S., P.S., A.S., D.S., K.T., R.T., A.T., C.T., M.v.B., J.W., R.W., B.W., M.V., A.Z., R.B., S.D., M.I., J.J., L.L., W.L., T.M., S.S., H.S., R.S.

Funding Sources

Aging Gene-Environment Susceptibility-Reykjavik Study: The research has been funded by the National Institute on Aging (NIA) contract N01-AG-12100 with contributions from the National Eye Institute (NEI), the National Institute on Deafness and Other Communication Disorders (NIDCD) and the National Heart, Lung, and Blood Institute (NHLBI), the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament).

Atherosclerosis Risk in Communities Study: The research is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and NIH contract HHSN268200625226C. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. Funds for this project were also supported by grant HL093029 to MF.

Austrian Stroke Prevention Study: The research reported in this article was funded by the Austrian Science Fond (FWF) grant number P20545-P05 and P13180. The Medical University of Graz supports the databank of the ASPs.

Cardiovascular Health Study: This CHS research was supported by National Heart, Lung, and Blood Institute (NHLBI) contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, N01HC15103; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, and R01HL120393 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Framingham Heart Study: From the Framingham Heart Study of the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health and Boston University School of Medicine. This work was supported by the NHLBI's Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. This study was also supported by grants from the National Institute of Neurological Disorders and Stroke (R01 NS17950), the National Institute of Aging (R01s AG08122, AG16495, AG033193, U0149505) and the NHLBI (U01 HL096917 and R01 HL093029).

Prospective Study of Pravastatin in the Elderly at Risk: The PROSPER study was supported by an investigator initiated grant obtained from Bristol-Myers Squibb. Prof. Dr. J. W. Jukema is an established clinical investigator of the Netherlands Heart Foundation (grant 2001 D 032). Support for genotyping was provided by the seventh framework program of the European commission (grant 223004) and by the Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging grant 050-060-810).

Rotterdam Study: The GWA database of the Rotterdam Study was funded through the Netherlands Organization of Scientific Research NWO (nr. 175.010.2005.011). This study was further supported by the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project nr. 050-060-810. The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University, Rotterdam; the Netherlands organization for scientific research (NWO), the Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The Rotterdam Scan Study was supported by the Netherlands Organization of Scientific Research (NWO) project nrs. 918-46-615; 904-61-096; 904-61-133; 948-00-010. Benjamin Verhaaren was supported by the Dutch Heart Foundation (Nederlandse Hartstichting), grant number 2009B102. Erasmus Medical Center was further supported by the Dutch Technology Foundation STW (Stichting Technische Wetenschappen) Perspectief programme ImaGene and the EU Seventh Framework Programme for Research (FP7) grant VPH-Dare@IT (Virtual Physiological Human: Dementia Research Enabled By IT).

Tasmanian Study of Cognition and Gait: The TASCOC study is supported by Project Grants from the National Health and Medical Research Council (NHMRC IDs 403000, 491109, 606543), and a grant from the Wicking Dementia Education and Research Centre, Hobart. Velandai Srikanth is supported by an NHMRC/National Heart Foundation Career Development Fellowship and a Heart Foundation Future Fellowship. Russell Thomson is supported by a NHMRC Project Grant.

Three City Study (3C): The 3C Study is conducted under a partnership agreement between the Institut National de la Santé et de la Recherche Médicale (INSERM), the Victor Segalen-Bordeaux II University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l'Éducation Nationale (MGEN), Institut de la Longévité, Conseils Régionaux de Aquitaine and Bourgogne, Fondation de France, and Ministry of Research-INSERM Programme "Cohortes et collections de

données biologiques." Lille Génopôle received an unconditional grant from Eisai. This work was supported by the National Foundation for Alzheimer's Disease and Related Disorders, the Institut Pasteur de Lille and the Centre National de Génotypage. Stéphanie Debette is recipient of a Chair of Excellence grant from the French National Research Agency (ANR). Christophe Tzourio and Stéphanie Debette are supported by a grant from the Fondation Leducq.

References

1. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. *Stroke*. 1998; 29:1177–1181. [PubMed: 9626291]
2. Atwood LD, Wolf PA, Heard-Costa NL, Massaro JM, Beiser A, D'Agostino RB, et al. Genetic variation in white matter hyperintensity volume in the framingham study. *Stroke*. 2004; 35:1609–1613. [PubMed: 15143299]
3. Turner ST, Jack CR, Fornage M, Mosley TH, Boerwinkle E, de Andrade M. Heritability of leukoaraiosis in hypertensive sibships. *Hypertension*. 2004; 43:483–487. [PubMed: 14718359]
4. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. *Lancet Neurol*. 2003; 2:89–98. [PubMed: 12849265]
5. Paternoster L, Chen W, Sudlow CL. Genetic determinants of white matter hyperintensities on brain scans: A systematic assessment of 19 candidate gene polymorphisms in 46 studies in 19,000 subjects. *Stroke*. 2009; 40:2020–2026. [PubMed: 19407234]
6. Freudenberger P, Schmidt R, Schmidt H. Genetics of age-related white matter lesions from linkage to genome wide association studies. *J Neurol Sci*. 2012; 322:82–86. [PubMed: 22795385]
7. Schmidt H, Zeginigg M, Wiltgen M, Freudenberger P, Petrovic K, Cavalieri M, et al. Genetic variants of the notch3 gene in the elderly and magnetic resonance imaging correlates of age-related cerebral small vessel disease. *Brain*. 2011; 134:3384–3397. [PubMed: 22006983]
8. Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, et al. Cohorts for heart and aging research in genomic epidemiology (charge) consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. *Circ Cardiovasc Genet*. 2009; 2:73–80. [PubMed: 20031568]
9. Fornage M, Debette S, Bis JC, Schmidt H, Ikram MA, Dufouil C, et al. Genome-wide association studies of cerebral white matter lesion burden: The charge consortium. *Ann Neurol*. 2011; 69:928–939. [PubMed: 21681796]
10. Verhaaren BF, de Boer R, Vernooij MW, Rivadeneira F, Uitterlinden AG, Hofman A, et al. Replication study of chr17q25 with cerebral white matter lesion volume. *Stroke*. 2011; 42:3297–3299. [PubMed: 21868733]
11. Adib-Samii P, Rost N, Traylor M, Devan W, Biffi A, Lanfranconi S, et al. 17q25 locus is associated with white matter hyperintensity volume in ischemic stroke, but not with lacunar stroke status. *Stroke*. 2013; 44:1609–1615. [PubMed: 23674528]
12. Tabara Y, Igase M, Okada Y, Nagai T, Uetani E, Kido T, et al. Association of chr17q25 with cerebral white matter hyperintensities and cognitive impairment: The jshipp study. *Eur J Neurol*. 2013; 20:860–862. [PubMed: 23020117]
13. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, et al. Age, gene/environment susceptibility-reykjavik study: Multidisciplinary applied phenomics. *Am J Epidemiol*. 2007; 165:1076–1087. [PubMed: 17351290]
14. investigators TA. The atherosclerosis risk in communities (aric) study: Design and objectives. *Am J Epidemiol*. 1989; 129:687–702. [PubMed: 2646917]
15. Schmidt R, Lechner H, Fazekas F, Niederkorn K, Reinhart B, Grieshofer P, et al. Assessment of cerebrovascular risk profiles in healthy persons: Definition of research goals and the austrian stroke prevention study (asps). *Neuroepidemiology*. 1994; 13:308–313. [PubMed: 7800110]
16. Schmidt R, Schmidt H, Pichler M, Enzinger C, Petrovic K, Niederkorn K, et al. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: Results of the austrian stroke prevention study. *Stroke*. 2006; 37:2910–2916. [PubMed: 17082472]
17. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The cardiovascular health study: Design and rationale. *Ann Epidemiol*. 1991; 1:263–276. [PubMed: 1669507]

18. Dawber TR, Kannel WB. The framingham study. An epidemiological approach to coronary heart disease. *Circulation*. 1966; 34:553–555. [PubMed: 5921755]
19. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The framingham offspring study. Design and preliminary data. *Prev Med*. 1975; 4:518–525. [PubMed: 1208363]
20. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, et al. The design of a prospective study of pravastatin in the elderly at risk (prosper). Prosper study group. Prospective study of pravastatin in the elderly at risk. *Am J Cardiol*. 1999; 84:1192–1197. [PubMed: 10569329]
21. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (prosper): A randomised controlled trial. *Lancet*. 2002; 360:1623–1630. [PubMed: 12457784]
22. Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, Kuipers EJ, et al. The rotterdam study: 2010 objectives and design update. *Eur J Epidemiol*. 2009; 24:553–572. [PubMed: 19728115]
23. Srikanth V, Beare R, Blizzard L, Phan T, Stapleton J, Chen J, et al. Cerebral white matter lesions, gait, and the risk of incident falls: A prospective population-based study. *Stroke*. 2009; 40:175–180. [PubMed: 18927448]
24. Group CS. Vascular factors and risk of dementia: Design of the three-city study and baseline characteristics of the study population. *Neuroepidemiology*. 2003; 22:316–325. [PubMed: 14598854]
25. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. *Am J Hum Genet*. 1998; 62:1198–1211. [PubMed: 9545414]
26. Willer CJ, Li Y, Abecasis GR. Metal: Fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010; 26:2190–2191. [PubMed: 20616382]
27. Dayem, Ullah AZ.; Lemoine, NR.; Chelala, C. Snpnexus: A web server for functional annotation of novel and publicly known genetic variants (2012 update). *Nucleic Acids Res*. 2012; 40:W65–70. [PubMed: 22544707]
28. Wang K, Li M, Hakonarson H. Annovar: Functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*. 2010; 38:e164. [PubMed: 20601685]
29. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. Snap: A web-based tool for identification and annotation of proxy snps using hapmap. *Bioinformatics*. 2008; 24:2938–2939. [PubMed: 18974171]
30. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. Locuszoom: Regional visualization of genome-wide association scan results. *Bioinformatics*. 2010; 26:2336–2337. [PubMed: 20634204]
31. eQTL Browser. [Accessed February 18, 2015] National center for biotechnology information web site. <http://www.ncbi.nlm.nih.gov/gtex/GTEX2/gtex.cgi>
32. Amar K, MacGowan S, Wilcock G, Lewis T, Scott M. Are genetic factors important in the aetiology of leukoaraiosis? Results from a memory clinic population. *Int J Geriatr Psychiatry*. 1998; 13:585–590. [PubMed: 9777422]
33. Hassan A, Lansbury A, Catto AJ, Guthrie A, Spencer J, Craven C, et al. Angiotensin converting enzyme insertion/deletion genotype is associated with leukoaraiosis in lacunar syndromes. *J Neurol Neurosurg Psychiatry*. 2002; 72:343–346. [PubMed: 11861692]
34. Sierra C, Coca A, Gomez-Angelats E, Poch E, Sobrino J, de la Sierra A. Reninangiotensin system genetic polymorphisms and cerebral white matter lesions in essential hypertension. *Hypertension*. 2002; 39:343–347. [PubMed: 11882570]
35. Kohara K, Fujisawa M, Ando F, Tabara Y, Niino N, Miki T, et al. Mthfr gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the japanese general population: The nils-isa study. *Stroke*. 2003; 34:1130–1135. [PubMed: 12690212]
36. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. *Brain*. 2004; 127:212–219. [PubMed: 14607791]
37. Gormley K, Bevan S, Markus HS. Polymorphisms in genes of the renin-angiotensin system and cerebral small vessel disease. *Cerebrovasc Dis*. 2007; 23:148–155. [PubMed: 17124396]

38. Schmidt R, Schmidt H, Fazekas F, Launer LJ, Niederkorn K, Kapeller P, et al. Angiotensinogen polymorphism m235t, carotid atherosclerosis, and small-vessel disease-related cerebral abnormalities. *Hypertension*. 2001; 38:110–115. [PubMed: 11463770]
39. van Rijn MJ, Bos MJ, Isaacs A, Yazdanpanah M, Arias-Vasquez A, Stricker BH, et al. Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology. *J Neurol Neurosurg Psychiatry*. 2007; 78:1083–1087. [PubMed: 17220293]
40. Bronge L, Fernaeus SE, Blomberg M, Ingelson M, Lannfelt L, Isberg B, et al. White matter lesions in alzheimer patients are influenced by apolipoprotein e genotype. *Dement Geriatr Cogn Disord*. 1999; 10:89–96. [PubMed: 10026381]
41. de Leeuw FE, Richard F, de Groot JC, van Duijn CM, Hofman A, Van Gijn J, et al. Interaction between hypertension, apoe, and cerebral white matter lesions. *Stroke*. 2004; 35:1057–1060. [PubMed: 15060316]
42. Lunetta KL, Erlich PM, Cuenco KT, Cupples LA, Green RC, Farrer LA, et al. Heritability of magnetic resonance imaging (mri) traits in alzheimer disease cases and their siblings in the mirage study. *Alzheimer Dis Assoc Disord*. 2007; 21:85–91. [PubMed: 17545732]
43. Høgh P, Garde E, Mortensen EL, Jørgensen OS, Krabbe K, Waldemar G. The apolipoprotein e epsilon4-allele and antihypertensive treatment are associated with increased risk of cerebral mri white matter hyperintensities. *Acta Neurol Scand*. 2007; 115:248–253. [PubMed: 17376122]
44. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: A framework for traditional and novel measures. *Epidemiology*. 2010; 21:128–138. [PubMed: 20010215]
45. Nagelkerke NJD. A note on a general definition of the coefficient of determination. *Biometrika*. 1991; 78:691–692.
46. Aberg KA, Liu Y, Bukszar J, McClay JL, Khachane AN, Andreassen OA, et al. A comprehensive family-based replication study of schizophrenia genes. *JAMA Psychiatry*. 2013; 70:573–581. [PubMed: 23894747]
47. Cross-Disorder Group of the Psychiatric Genomics C. Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. *Lancet*. 2013; 381:1371–1379. [PubMed: 23453885]
48. Schizophrenia Psychiatric Genome-Wide Association Study C. Genome-wide association study identifies five new schizophrenia loci. *Nat Genet*. 2011; 43:969–976. [PubMed: 21926974]
49. Lesov-Schlaggar CN, Hardin J, DeCarli C, Krasnow RE, Reed T, Wolf PA, et al. Longitudinal genetic analysis of brain volumes in normal elderly male twins. *Neurobiol Aging*. 2012; 33:636–644. [PubMed: 20630620]
50. McGue M, Christensen K. The heritability of level and rate-of-change in cognitive functioning in danish twins aged 70 years and older. *Exp Aging Res*. 2002; 28:435–451. [PubMed: 12227922]
51. Reynolds CA, Finkel D, McArdle JJ, Gatz M, Berg S, Pedersen NL. Quantitative genetic analysis of latent growth curve models of cognitive abilities in adulthood. *Dev Psychol*. 2005; 41:3–16. [PubMed: 15656733]
52. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nat Genet*. 2013; 45:1150–1159. [PubMed: 23974872]
53. Bergen SE, O'Dushlaine CT, Ripke S, Lee PH, Ruderfer DM, Akterin S, et al. Genome-wide association study in a swedish population yields support for greater cnv and mhc involvement in schizophrenia compared with bipolar disorder. *Mol Psychiatry*. 2012; 17:880–886. [PubMed: 22688191]
54. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. *Nat Genet*. 2009; 41:666–676. [PubMed: 19430483]
55. Ho JE, Levy D, Rose L, Johnson AD, Ridker PM, Chasman DI. Discovery and replication of novel blood pressure genetic loci in the women's genome health study. *J Hypertens*. 2011; 29:62–69. [PubMed: 21045733]

56. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*. 2011; 478:103–109. [PubMed: 21909115]
57. Kelly TN, Takeuchi F, Tabara Y, Edwards TL, Kim YJ, Chen P, et al. Genome-wide association study meta-analysis reveals transethnic replication of mean arterial and pulse pressure loci. *Hypertension*. 2013; 62:853–859. [PubMed: 24001895]
58. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet*. 2011; 43:333–338. [PubMed: 21378990]
59. Yasuno K, Bilguvar K, Bijlenga P, Low SK, Kirschke B, Auburger G, et al. Genome-wide association study of intracranial aneurysm identifies three new risk loci. *Nat Genet*. 2010; 42:420–425. [PubMed: 20364137]
60. Edwards M, Hall J, Gong G, O'Bryant SE. Arsenic exposure, as3mt polymorphism, and neuropsychological functioning among rural dwelling adults and elders: A cross-sectional study. *Environ Health*. 2014; 13:15. [PubMed: 24621105]
61. Soleimani M. Na⁺:Hco₃⁻ cotransporters (nbc): Expression and regulation in the kidney. *J Nephrol*. 2002; 15(Suppl 5):S32–40. [PubMed: 12027220]
62. Amlal H, Burnham CE, Soleimani M. Characterization of na⁺/hco₃⁻ cotransporter isoform nbc-3. *Am J Physiol*. 1999; 276:F903–913. [PubMed: 10362779]
63. Grichtchenko II, Choi I, Zhong X, Bray-Ward P, Russell JM, Boron WF. Cloning, characterization, and chromosomal mapping of a human electroneutral na⁽⁺⁾-driven cl-hco₃ exchanger. *J Biol Chem*. 2001; 276:8358–8363. [PubMed: 11133997]
64. Debette S, Bis JC, Fornage M, Schmidt H, Ikram MA, Sigurdsson S, et al. Genome-wide association studies of mri-defined brain infarcts: Meta-analysis from the charge consortium. *Stroke*. 2010; 41:210–217. [PubMed: 20044523]
65. Dering M, Csanadi E, Gesierich B, Jouvent E, Herve D, Seiler S, et al. Incident lacunes preferentially localize to the edge of white matter hyperintensities: Insights into the pathophysiology of cerebral small vessel disease. *Brain*. 2013; 136:2717–2726. [PubMed: 23864274]
66. Jones RM, Cadby G, Blangero J, Abraham LJ, Whitehouse AJ, Moses EK. Macrod2 gene associated with autistic-like traits in a general population sample. *Psychiatr Genet*. 2014; 24:241–248. [PubMed: 25360606]
67. Awad IA, Spetzler RF, Hodak JA, Awad CA, Carey R. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. I. Correlation with age and cerebrovascular risk factors. *Stroke*. 1986; 17:1084–1089. [PubMed: 3810705]
68. Fazekas F, Niederkorn K, Schmidt R, Offenbacher H, Horner S, Bertha G, et al. White matter signal abnormalities in normal individuals: Correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. *Stroke*. 1988; 19:1285–1288. [PubMed: 3051534]




Figure 1. Genome-wide Manhattan plot for progression of WML

The Manhattan plot for the GWAS without adjustment for WML burden at baseline is shown in the upper panel and the Manhattan plot for the GWAS adjusted for WML burden at baseline is shown in the lower panel. The plot shows the $-\log_{10}(\text{p-values})$ for all SNPs in the analysis against their genomic position. Within each chromosome, shown on the x -axis, the results are plotted left to right from the p -terminal end. The red line represents the threshold for genome wide significance (5×10^{-8}), and the blue line represents the threshold for highly suggestive SNPs (1×10^{-5}).




Figure 2. Regional association plots for WML progression SNPs in loci 10q24.32, 12q13.13, 20p12.1, 4p15.31

The plots for locus 10q24.32 (A) and 12q13.13 (B) are shown in the upper panel, and the plots for locus 20p12.1 (C) and 4p15.31 (D) are shown in the lower panel. For loci 10q24.32, 12q13.13, and 20p12.1 associations were determined by WML progression GWAS meta-analysis in the model without adjustment for WML burden at baseline. For locus 4p15.31 the associations were determined by WML progression GWAS meta-analysis in the model with adjustment for WML burden at baseline. Plots are centered on the most significant SNP at a given locus along with the meta-analysis results for SNPs in a region surrounding it ($\pm 200\text{kb}$). All SNPs are plotted with their meta-analysis p-values against their genomic position, with the most significant SNP in the region indicated as a diamond and other SNPs shaded according to their pairwise correlation (r^2) with the signal SNP. The blue line represents the estimated recombination rates. Gene annotations are shown as dark blue line. The boxes at the end of the genes show the 5' and 3' UTRs, while boxes within the gene represent exons. Arrows indicate the direction of transcription.

Table 1

Performance of WML progression risk models.

	Model 1	Model 2	Model 3	Model 2 – Model 1	Model 3 – Model 1
ASPS	Without WML burden adjustment	0.146	0.226	0.275	
	With WML burden adjustment	0.433	0.519	0.550	0.117
CHS	Without WML burden adjustment	0.023	0.051	0.068	
	With WML burden adjustment	0.045	0.072	0.089	0.027
FHS	Without WML burden adjustment	0.113	0.130	0.143	
	With WML burden adjustment	0.172	0.183	0.194	0.011
PROSPER	Without WML burden adjustment	0.057	0.095	0.143	
	With WML burden adjustment	0.320	0.392	0.410	0.072
RS II	Without WML burden adjustment	0.149	0.164	0.199	
	With WML burden adjustment	0.391	0.408	0.453	0.017
RS III	Without WML burden adjustment	0.119	0.146	0.158	
	With WML burden adjustment	0.397	0.419	0.405	0.022
3C-Dijon	Without WML burden adjustment	0.054	0.106	0.118	
	With WML burden adjustment	0.203	0.247	0.259	0.044

Data are Nagelkerke's R².

Model 1): WML progression ~ age + sex + time + hypertension + diabetes + current smoking* without or with adjustment for WML burden at baseline

Model 2): WML progression ~ age + sex + time + hypertension + diabetes + current smoking* + GWAS SNPs without or with adjustment for WML burden at baseline

Model 3): WML progression ~ age + sex + time + hypertension + diabetes + current smoking* + GWAS SNPs + previously reported SNPs + APOE4 without or with adjustment for WML burden at baseline

* Frequency of current smoking ranged between 5.9% in 3C-Dijon and 24.5% in RS III.

ASPS: Austrian Stroke Prevention Study, CHS: Cardiovascular Health Study, FHS: Framingham Heart Study, PROSPER: Prospective Study of Pravastatin in the Elderly at Risk, RS II: Rotterdam Study II, RS III: Rotterdam Study III, 3C-Dijon: Three-City Dijon study